{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-273959","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.381504+00:00","generated_at":"2026-05-29T05:19:20.643971+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NewAmsterdam reports positive Phase 3 BROADWAY topline: 33% LDL-C reduction, 21% MACE reduction","bullets":["Primary endpoint met: LS mean LDL-C reduction of 33% (p<0.0001) vs placebo at day 84 on top of maximally tolerated therapies.","Observed 21% reduction in MACE (exploratory endpoint) at one year; hazard ratio 0.79 (95% CI 0.54-1.15).","Obicetrapib well-tolerated: TEAEs 59.8% vs placebo 60.9%; discontinuation 11.1% vs 12.4%.","NewAmsterdam plans to present additional BROADWAY data at upcoming medical meetings and discuss filings with regulators."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-273959","json":"https://secwatch.observer/filing/0001193125-24-273959.json","markdown":"https://secwatch.observer/filing/0001193125-24-273959.md","text":"https://secwatch.observer/filing/0001193125-24-273959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524273959/0001193125-24-273959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524273959/d910195d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:19:20.643971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}